Abstract Background Direct oral anticoagulants (DOACs) are widely used for secondary
prevention of venous thromboembolism (VTE) but their clinical efficacy and safety are not …

Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised
by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid …

Background This is the 2nd update to the 9th edition of these guidelines. We provide
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …

The objective was to develop evidence-based recommendations for the management of
antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature …

Clarity and guidance is required with regard to the use of direct oral anticoagulants in
antiphospholipid syndrome (APS) patients, within the confines of the recent European …

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by
arterial and venous thrombotic manifestations and/or pregnancy-related complications in …

Antiphospholipid antibody syndrome (APS) requires long-term anticoagulation to prevent
recurrent thrombosis. Direct oral anticoagulants (DOACs) have been increasingly used in …

This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to
describe outcomes in children treated with dabigatran etexilate for secondary venous …

Background The gold standard for secondary thromboprophylaxis in APS is long term
anticoagulation with vitamin K antagonists (VKAs). Because of their widespread use and …

Objective To perform a systematic literature review (SLR) informing the European
Lmmendations for the management of antiphospholipid syndrome (APS) in adults. Methods …